Hypertrophic Cardiomyopathy 

Hypertrophic cardiomyopathy (HCM) is cited as the most common inherited heart condition and has existed in the medical literature for over 150 years although its initial best description occurred in 1958. It is estimated that approximately 1 million individuals in the United States and approximately 20 million worldwide are at risk for carrying the genetic mutations associated with HCM.

HCM affects individuals regardless of ethnicity and sex, and can present at any age. Despite several advances in medical and surgical treatments, HCM related illness and death rates remain frustratingly significant highlighting the ongoing need for scientific and clinical advancement. The management of HCM remains complex ranging from its genetic heterogeneity to diagnosis to predicting and treating risk for heart failure and/or ventricular arrhythmias. These topics attract interest from a wide spectrum of medical disciplines from HCM clinical experts to geneticists to cardiac imagers to surgeons and translational scientists.


To bring together an innovative and productive community of physicians, scientists and medical providers dedicated to improving the diagnosis and treatment of people with hypertrophic cardiomyopathy through clinical excellence, research and education.


To enable HCM patients live productive and fulfilling lives.

Member Benefits

  • Opportunity to to engage and share data and education with manufacturers, institutions and pharmaceutical companies that provide treatment solutions for HCM.
  • Opportunity to engage in HCM education and research in areas that include diagnostic approaches, development of new therapies and techniques, and improving public awareness. 


Interested in becoming a member of HCMS? Click here to join as a member

In the News

  • Membership Now Open!


Tel: (919) 573-1308
Fax: (919)787-4916


3739 National Dr. Raleigh NC, 27612

Powered by Wild Apricot Membership Software